Psoriasis. Definition and Classification of A Complex Entity
Main Article Content
Abstract
Psoriasis, a chronic inflammatory skin condition influenced by hereditary factors and immune system response, exhibits diverse clinical manifestations. While its global incidence is around 2%, prevalence varies across geographical regions and ethnicities. The most common form, psoriasis vulgaris, presents as red, itchy patches with silver-colored scales, predominantly affecting the trunk, limbs, and scalp. Other clinical subtypes include inverse psoriasis, guttate psoriasis, pustular psoriasis, and erythrodermic psoriasis, each with distinct features and impacts. Beyond skin manifestations, psoriasis is associated with various co-occurring medical conditions, including hyperlipidemia, hypertension, coronary artery disease, type 2 diabetes, and obesity. Psoriasis patients have an increased risk of cardiovascular disease, with severity correlating with the incidence of diabetes and cardiovascular events. Additionally, psoriatic arthritis affects around 40% of patients and is often accompanied by nail involvement. Recent studies utilizing imaging techniques like 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) and nuclear magnetic resonance spectroscopy have shed light on systemic inflammation and cardiovascular risk in psoriasis patients. Treatments targeting IL-23 and IL-17 have shown promising results, though long-term efficacy and drug survival remain areas of concern. Psoriasis profoundly impacts patients' quality of life, with psychological distress comparable to cancer and depression. However, treatment can significantly alleviate symptoms and improve overall well-being. Ongoing research aims to expand treatment options, particularly targeting novel molecular pathways. In conclusion, while significant progress has been made in understanding and treating psoriasis, challenges remain in optimizing therapy selection and long-term management. Further research is warranted to elucidate the complex genetic and immunological underpinnings of the disease and to enhance treatment outcomes for affected individuals
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Unissa, R., Kumar, P. M., Pasha, M., Begum, S., & Maheswari, B. (2019). Psoriasis: a comprehensive review. Asian journal of Research in pharmaceutical science, 9(1), 29-38.
II. Albanesi, C. (2019). Immunology of psoriasis. In Clinical immunology (pp. 871-878). Elsevier.
III. Afonina, I. S., Van Nuffel, E., & Beyaert, R. (2021). Immune responses and therapeutic options in psoriasis. Cellular and Molecular Life Sciences, 78, 2709-2727.
IV. Benezeder, T., & Wolf, P. (2019, November). Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease). In Seminars in Immunopathology (Vol. 41, No. 6, pp. 633-644). Berlin/Heidelberg: Springer Berlin Heidelberg.
V. Raut, A. S., Prabhu, R. H., & Patravale, V. B. (2013). Psoriasis clinical implications and treatment: a review. Critical Reviews™ in Therapeutic Drug Carrier Systems, 30(3).
VI. Raut, A. S., Prabhu, R. H., & Patravale, V. B. (2013). Psoriasis clinical implications and treatment: a review. Critical Reviews™ in Therapeutic Drug Carrier Systems, 30(3).
VII. Micali, G., Verzì, A. E., Giuffrida, G., Panebianco, E., Musumeci, M. L., & Lacarrubba, F. (2019). Inverse psoriasis: from diagnosis to current treatment options. Clinical, cosmetic and investigational dermatology, 953-959.
VIII. Leung, A. K., Barankin, B., Lam, J. M., & Leong, K. F. (2023). Childhood guttate psoriasis: an updated review. Drugs in context, 12.
IX. Wang, H., & Jin, H. (2021). Update on the aetiology and mechanisms of generalized pustular psoriasis. European Journal of Dermatology, 31(5), 602-608.
X. Singh, R. K., Lee, K. M., Ucmak, D., Brodsky, M., Atanelov, Z., Farahnik, B., ... & Liao, W. (2016). Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis: Targets and Therapy, 93-104.
XI. Davidovici, B. B., Sattar, N., Jörg, P. C., Puig, L., Emery, P., Barker, J. N., ... & Krueger, J. G. (2010). Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. Journal of Investigative Dermatology, 130(7), 1785-1796.
XII. Mehta, N. N., Yu, Y., Saboury, B., Foroughi, N., Krishnamoorthy, P., Raper, A., ... & Gelfand, J. M. (2011). Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography–computed tomography (FDG-PET/CT): a pilot study. Archives of dermatology, 147(9), 1031-1039.
XIII. Kim, B. S., Lee, W. K., Pak, K., Han, J., Kim, G. W., Kim, H. S., ... & Kim, S. J. (2019). Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study using 18F-fluorodeoxyglucose PET/CT. Journal of the American Academy of Dermatology, 80(5), 1322-1331.
XIV. FitzGerald, O., Ogdie, A., Chandran, V., Coates, L. C., Kavanaugh, A., Tillett, W., ... & Mease, P. J. (2021). Psoriatic arthritis. Nature reviews Disease primers, 7(1), 59.
XV. Reich, K. (2012). The concept of psoriasis as a systemic inflammation: implications for disease management. Journal of the European Academy of Dermatology and Venereology, 26, 3-11.
XVI. 16. Blackstone, B., Patel, R., & Bewley, A. (2022). Assessing and improving psychological well-being in psoriasis: considerations for the clinician. Psoriasis: Targets and Therapy, 25-33.